Precision Medicine Applications in Oncology Webinar Series

Driven by the increased emphasis on precision and personalized approaches to drug development, Covance will be delivering a webinar series to look at specific challenges and opportunities with current and future applications in oncology.

The series kicks off with a view of trends in immunotherapies including preclinical model selection, biomarkers of safety and efficacy, and specific trial design and medical monitoring considerations.

Other topics will delve into:

  • Adoptive T-cell therapies, addressing safety assessment and monitoring tools from preclinical through clinical development 
  • Considerations for clinical trial design and execution for novel targeted therapies and immunotherapies
  • Biomarker technologies for the detection of rare cancer driver mutations and novel targeted therapies
  • Applications for liquid biopsy technologies

We look forward to seeing you in one or all of these webinars - in the live sessions or on demand.

Now Available On-Demand

  • Learn the brief history of advances in adoptive T-cell therapies

  • Gain strategies for assessing safety and possible efficacy to navigate regulatory pathways to the clinic

  • Understand the role of biomarkers used to assess and monitor pharmacokinetics of the treatment dosing, level of the target cell population and other monitors of treatment efficacy

  • Hear about the latest guidelines for assessment and management of potential toxicities

Presented by:

Brian E. McIntosh, PhD
Study Director and Scientific Lead, Cell, Gene and Regenerative Therapies, Covance

Akanksha Gupta, PhD 
Head, Immunology, Biomarker Solution Center, Covance

Carlo Lanza, MD, PhD
Executive Medical Officer, Covance and Subject Matter Expert in Hematology Oncology

Preclinical Pharmacology, Toxicology & Pharmacokinetics 
Thursday, 18 June 2020, 10:00 am EDT/3:00 pm BST

In this webinar, attendees will learn about and understand

  • In vitro verification of product function
  • Animal model selection in preclinical studies
  • Pharmacology and toxicity studies to guide determination of biologically relevant and clinically safe dose levels
  • The biological disposition of product including tumor cell infiltration, persistence and viral shedding

Presented by:

Maryland Franklin, PhD
Executive Director of Scientific Development, Preclinical Oncology

Brian E. McIntosh, PhD

Study Director and Scientific Lead Cell, Gene and Regenerative Therapies